MARKET

SBPH

SBPH

Spring Bk Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.450
+0.050
+1.47%
Opening 15:08 12/10 EST
OPEN
3.330
PREV CLOSE
3.400
HIGH
3.570
LOW
3.330
VOLUME
233.60K
TURNOVER
--
52 WEEK HIGH
11.90
52 WEEK LOW
2.750
MARKET CAP
56.84M
P/E (TTM)
-2.5694
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SBPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SBPH News

  • Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019
  • GlobeNewswire.1d ago
  • Spring Bank Pharmaceuticals' Inarigivir Just Isn't Promising For Treating HBV
  • Seeking Alpha - Article.11/29 21:50
  • Edited Transcript of SBPH earnings conference call or presentation 11-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.11/28 04:19
  • Spring Bank Announces Dosing of Patients in Phase 1 Clinical Trial of IV-Administered STING Agonist, SB 11285
  • GlobeNewswire.11/20 14:00

More

Industry

Biotechnology & Medical Research
+0.61%
Pharmaceuticals & Medical Research
+0.72%

Hot Stocks

Name
Price
%Change

About SBPH

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company's SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).
More

Webull offers Spring Bank Pharmaceuticals Inc (SBPH) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.